Direxion Daily S&P Biotech Bear 3X ETF
LABD
11 hedge funds and large institutions have $13.8M invested in Direxion Daily S&P Biotech Bear 3X ETF in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 2 closing their positions.
138% more call options, than puts
Call options by funds: $24.7M | Put options by funds: $10.4M
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
1.94% less ownership
Funds ownership: 17.09% → 15.15% (-1.9%)
8% less funds holding
Funds holding: 12 → 11 (-1)
13% less capital invested
Capital invested by funds: $15.8M → $13.8M (-$2.08M)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$779K |
| 2 |
Jane Street
New York
|
+$535K |
| 3 |
HF
HRT Financial
New York
|
+$350K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$320K |
| 5 |
Morgan Stanley
New York
|
+$84.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$1.9M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$952K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$392K |
| 4 |
MMA
Miracle Mile Advisors
Los Angeles,
California
|
-$359K |
| 5 |
Citigroup
New York
|
-$244K |
LABD Hedge Fund Activity: Q2 2019 in Review
11 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) for Q2 2019, worth a combined $13.8M — down 13% from $15.8M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of LABD and 1 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 4 added.
The largest buyer was Bellevue Group, adding an estimated $779K. The largest seller was Virtu Financial, cutting an estimated $1.9M.
- 11 institutional investors held Direxion Daily S&P Biotech Bear 3X ETF (LABD) as of Q2 2019, down from 12 in Q1 2019.
- Funds reported $13.8M of Direxion Daily S&P Biotech Bear 3X ETF stock for Q2 2019, down 13% quarter-over-quarter.
- 1 fund opened new Direxion Daily S&P Biotech Bear 3X ETF positions in Q2 2019 and 2 closed out, a net change of -1 holder.
- The largest Direxion Daily S&P Biotech Bear 3X ETF buyer in Q2 2019 was Bellevue Group, an estimated $779K added.
- The largest Direxion Daily S&P Biotech Bear 3X ETF seller in Q2 2019 was Virtu Financial, an estimated $1.9M sold.
Based on aggregated 13F filings for Q2 2019.